Researcher:
Zorman, Yılmaz

Loading...
Profile Picture
ORCID

Job Title

Doctor

First Name

Yılmaz

Last Name

Zorman

Name

Name Variants

Zorman, Yılmaz

Email Address

Birth Date

Search Results

Now showing 1 - 2 of 2
  • Placeholder
    Publication
    Iatrogenic non-coronary leaflet perforation as a complication after robotic mitral valve repair
    (BMC, 2024) Shatelen, Nataliia; Kalangos, Afksendiyos; Zorman, Yılmaz; Çeliker Güler, Emel; School of Medicine; Koç University Hospital
    Iatrogenic aortic regurgitation secondary to leaflet injury is a rare complication of mitral valve surgery. For the first time, we report a patient who had progressive aortic regurgitation due to non-coronary leaflet perforation after robotic mitral valve repair and required aortic valve repair 18 months after this initial surgery. As in our case, aortic regurgitation after mitral valve surgery may remain undiagnosed on intraoperative transesophageal echocardiography or undetected until the patient's discharge due to gradual enlargement of very small perforations over the postoperative course.
  • Thumbnail Image
    PublicationOpen Access
    Short and oral antimicrobial therapy for diabetic foot infection: a narrative review of current knowledge
    (Copernicus Publications, 2022) Maurer, S.M.; Hepp, Z.S.; McCallin, S.; Waibel, F.W.A.; Romero, F.C.; Lipsky, B.A.; Uçkay, I.; Zorman, Yılmaz; Koç University Hospital
    Diabetic foot infection is a frequent complication in long-standing diabetes mellitus. For antimicrobial therapy of this infection, both the optimal duration and the route of administration are often based more on expert opinion than on published evidence. We reviewed the scientific literature, specifically seeking prospective trials, and aimed at addressing two clinical issues: (1) shortening the currently recommended antibiotic duration and (2) using oral (rather than parenteral) therapy, especially after the patient has undergone debridement and revascularization. We also reviewed some older key articles that are critical to our understanding of the treatment of these infections, particularly with respect to diabetic foot osteomyelitis. Our conclusion is that the maximum duration of antibiotic therapy for osteomyelitis should be no more than to 4-6 weeks and might even be shorter in selected cases. In the future, in addition to conducting randomized trials and propagating national and international guidance, we should also explore innovative strategies, such as intraosseous antibiotic agents and bacteriophages.